R. Facklam

New England Journal of Medicine · 2002–2006

A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Who trusts R. Facklam overall

  1. A. E. Clark
  2. E. Kaleta
  3. Amit Arora
  4. Donna M. Wolk

Papers from R. Facklam's perspective

Ordered by how strongly the researchers R. Facklam trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. (Jornal de Pediatria)
  2. Package. (Surgery, gynecology & obstetrics)
  3. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro (Cell Discovery)
  4. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial (International Journal of Antimicrobial Agents)
  5. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study (The Lancet)
  6. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR (Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin)
  7. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study (Lancet. Infectious Diseases (Print))
  8. Viral dynamics in mild and severe cases of COVID-19 (Lancet. Infectious Diseases (Print))
  9. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
  10. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial (medRxiv)

Their papers